Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011447 | 0.76 | CD44 (0.32) | PARP1ALDH1A1 | |
| SCHEMBL4854314 | 0.68 | SLC6A2 (0.37) | PARP1PARP10PARP11HTR2CCYP1A2 | |
| SCHEMBL5545200 | 0.68 | HTR2C (0.32) | HTR2CKDM4ECYP1A2CYP2A6CA1 | |
| SCHEMBL846505 | 0.66 | PARP1 (0.39) | PARP1CA1CA2 | |
| SCHEMBL6789771 | 0.66 | PARP1 (0.39) | PARP1CA1CA2 | |
| SCHEMBL15902739 | 0.66 | PARP1 (0.39) | PARP1CA1CA2 | |
| SCHEMBL19692682 | 0.65 | PARP1 (0.34) | PARP1PARP10PARP11CYP1A2CYP2A6 | |
| SCHEMBL15181349 | 0.64 | PARP1 (0.41) | PARP1PARP10PARP11KDM4ECYP1A2 | |
| SCHEMBL13833541 | 0.64 | PARP1 (0.47) | PARP1PARP10PARP11HTR2CCYP1A2 | |
| SCHEMBL16131317 | 0.64 | CA1 (0.38) | PARP1HTR2CCYP2A6ACHECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | claimed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | claimed |
| EP-2918589-B1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | INTELLIKINE LLC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010077589-A2 | STAT3 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN OFFICE OF TECHNOLOGY TRANSFER (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010025235-A1 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-04 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PARP1 4420/4885PARP10 4531/4885PARP11 3491/4885 |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | DRD3, HTR3C, HTR3A | PARP1 4596/4885PARP10 3495/4885PARP11 3960/4885 |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | STAT3, JAK2, STAT6 | PARP1 2596/4885PARP10 1502/4885PARP11 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.